June 30, 2021 | Portfolio News

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

22

Novel FDA PMA & de novo 510k approvals

61

U.S. Commercial Product Launches

40

Level I Clinical Trials

34

Strategic Financings

32

Exits by IPO or M&A